-
The Pan-Cancer Dynamics of Natural Killer Cells: Insights into Heterogeneity and Dysfunction
The immune system’s frontline defenders, Natural Killer (NK) cells, play a pivotal role in the innate immune response against tumor progression. To deepen our understanding of their intricacies within the…
-
ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope
Editor’s Note: Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought…
-
Professor Ying Fan: Evolution of HR+/HER2- Early Breast Cancer Adjuvant Treatment Strategies and Risk Stratification—Based on the Chinese Perspective
Editor’s Note Breast cancer is the most common malignancy in women, with an increasing incidence in recent years. HR+/HER2- breast cancer accounts for approximately 70% of all breast cancer cases,…
-
ESMO Big Shot Interview | Professor Feng Wang: Significant Efficacy of Sintilimab Combined with Apatinib and Bevacizumab in the Treatment of MSS/pMMR Metastatic Colorectal Cancer, Promising Future
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain from October 20 to 24. The Oncology Frontier Reporting Team delved into the frontiers of international advancements, witnessing the progress of China’s anti-cancer efforts on the global stage. Professor Feng Wang from Sun Yat-sen University Cancer Center presented an important…
-
Dr. Yanhang Gao’s Team: Non-Invasive Screening for ANA-Positive DILI Patients with AIH-Like Histological Features, Aiding in Precise Liver Biopsy!
Drug-induced liver injury (DILI) can mimic all features of acute and chronic liver diseases, including autoimmune hepatitis (AIH). Both conditions exhibit similarities in serology and histology, including the presence of…
-
Dr. Jun Li’s Team: ETS2 as a Potential New Target for the Diagnosis and Treatment of HBV-ACLF, Alleviating Liver Failure Progression by Suppressing Macrophage Immune Inflammatory Response
Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a complex syndrome characterized by acute liver failure on the basis of chronic hepatitis B, triggered by various factors, with a short-term…
-
Dr. George-Lau: Advances and Reflections on Hepatitis B and Hepatitis D New Therapies
At the 58th European Association for the Study of the Liver (EASL) Annual Meeting (EASL2023) and the 2023 EASL Congress, one of the highlights was the emergence of new antiviral…
-
ESMO Expert Commentary | Professor Xinxiang Li: Rechallenge with EGFR Inhibitors in ctDNA RAS/BRAF Wild-Type Refractory mCRC Provides New Perspectives for Colorectal Cancer Treatment
Editor’s Note:The European Society for Medical Oncology (ESMO) annual meeting in Madrid, Spain has proceeded as scheduled. “Oncology Frontier” has selected key research reported at ESMO 2023 for commentary by…
Connecting Medical Expertise through Media